United Therapeutics: A Record Quarter That Quietly Pushed Its Biggest Launches Right
Tyvaso posts a best-ever quarter and the Liquidia settlement buys clarity on PH-ILD — but the soft-mist inhaler slips to 2027 and the triple pill is 'treading water.'
UTHR · Earnings Call · 2026-11-04
The Quarter That Wasn't Supposed To Be About Regulatory Delay
United Therapeutics came into this call with momentum. The stock is +12.3% over the last 90 days, a clean one-segment grind higher, and management delivered the number the tape wanted: record total revenue of $833 million and record Tyvaso revenue of $504 million. Michael Benkowitz did not undersell it — “this quarter's results, our best quarter ever, demonstrate that execution and reinforce our conviction that our business has regained meaningful momentum.” — Michael Benkowitz, Chief Financial Officer or Senior Financial Executive · 2026-11-04 He also flagged “over 1,000 referrals for a UT product in October, the most ever received in a single month.” — Michael Benkowitz, Chief Financial Officer or Senior Financial Executive · 2026-11-04
That matters because the prior twelve months were ugly on the top line: the June quarter printed $783 million, 2% below the year-ago period — the first down year-over-year revenue comparison in a long stretch of up-3y:+108%, up-12y:+182% growth. The September print reverses that. But the same call that delivered the record also delivered two regulatory step-backs, and the market's attention should be on those.
Two Launches Move Right, And Management Says Little
First: the soft mist inhaler. In February, Martine Rothblatt all but promised it:
We are unsheathing this product today because it will be filed this year for commercial launch next year.
Nine months later, Pat Poisson's answer to a simple filing-timing question was a polite retreat: “we now expect to submit the NDA in 2027 and not at the end of this year.” — Pat Poisson, Executive or Senior Management (likely in Regulatory or Clinical Affairs) · 2026-11-04 When pressed on what the FDA wanted, he was adamant it was nothing new — “Following that discussion, we've now determined that additional work is going to be needed to support the application” — Pat Poisson, Executive or Senior Management (likely in Regulatory or Clinical Affairs) · 2026-11-04 — and later, “It's just generating additional data. I don't think we're particularly worried about it. It's just we need time to do it.” — Pat Poisson, Executive or Senior Management (likely in Regulatory or Clinical Affairs) · 2026-11-04
Second, and quieter: the triple oral pill. Roger Song asked for the path forward and got “we're just treading water while we work on different options that we can present to them.” — Pat Poisson, Executive or Senior Management (likely in Regulatory or Clinical Affairs) · 2026-11-04 That is the language of a program without a regulatory route, not one with a timing issue.
And underneath both, Ash Verma surfaced an OAI compliance status at the ralinepag API supplier. Poisson framed it as "priority one" to resolve ahead of the June 24, 2027 PDUFA date, with contingency plans "progressing in parallel." The company has time — but the pattern across this call is that the super prostacyclin narrative, which peaked as the company's top keyword in the February quarter, has cooled: the theme slid hard in the most recent quarters as the story migrated from clinical catalysts to supply-chain and filing mechanics.
What The Settlement Actually Bought
The genuinely new theme — and the one that explains why the tape has been kind — is settlement. The court upheld UT's intellectual property and, in Benkowitz's words, the terms were “ultimately removing PH-ILD from the YUTREPIA label, preventing its promotion and marketing into that indication, and prohibiting Liquidia from encouraging off-label usage, which we will be monitoring very closely.” — Michael Benkowitz, Chief Financial Officer or Senior Financial Executive · 2026-11-04 Read functionally, YUTREPIA is now boxed out of the largest growth pool, and UT has base business clarity it did not have a quarter ago.
What it does not buy is patient conversion. Asked directly about patient switch dynamics, Benkowitz was explicit that the damages structure contemplated no mandatory migration, and that stable YUTREPIA patients will likely stay put. The opportunity is new prescriptions, not recapture — consistent with his own framing on prior calls, where he repeatedly described competitor launches as growing the addressable pie rather than stealing from it. The recurring analyst question has finally gotten a structural answer instead of a reassurance.
What is doing real work on the P&L is the humbler stuff: the 80-microgram cartridge and higher-strength kits that let one breath replace fifteen nebulized breaths. The higher dose theme, second only to PH-COPD in this quarter's keyword set, is where the revenue mechanics live — Benkowitz noted roughly one in three new DPI starts now reaches higher doses, double the prior rate.
The Theme Management Stopped Talking About
The most revealing absence is IPF. nebulized Tyvaso in IPF was the single dominant keyword in the June quarter, with the sales-force doubling explicitly justified against it. This quarter it is effectively gone from the narrative. For a company whose February messaging was built on a $4 billion run-rate and a launch that would "bend the curve," the silence is notable — the forward story has been re-cut around PH COPD (the new top keyword, a Phase II-stage opportunity rather than a near-term launch) and around ralinepag's less glamorous but nearer PDUFA.
The capital allocation rhymes with that. Buying down Arena's ralinepag royalty — “we looked at this more as an opportunistic use of capital, kind of in our overall capital allocation waterfall” — James Edgemond, Executive or Senior Management (likely in Business Development or Finance) · 2026-11-04 — is a company telling you it values the certainty of an approval it already has filed over the optionality of one it hasn't.
The Balance Sheet Buys The Time
Here is why the slippage didn't break the stock. Effective net cash stands at $9.0 billion, up from roughly $3 billion two years ago, against a $25.8 billion market cap. Interest coverage of 128x and liabilities at just 11.4% of assets make this one of the cleaner balance sheets in specialty pharma. Gross margin of 87.3% is off the mid-90s peak but still elite.
The valuation has re-rated hard into the story: 7.3x price-to-revenue, up 74% year-over-year, and 14.6x price-to-operating-income. That is the tension in one line: the multiple has already been paid for execution, and this quarter's execution was commercial, not regulatory.
The verdict. United Therapeutics won the fight it needed to win — the litigation — and delivered the commercial quarter bulls wanted. But it quietly moved two of its three flagship launches to the right, and the keyword record shows management has already re-narrated toward PH-COPD and base-business durability. The referral inflection Benkowitz describes is real and datable to mid-September; the question for the next two quarters is whether commercial momentum can carry a stock that just discovered its pipeline calendar has more slack in it than advertised.